Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.28 USD | -5.61% | +1.76% | +116.83% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+116.83% | 662M | |
+18.40% | 125B | |
+13.92% | 109B | |
-3.20% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-11.65% | 16.64B | |
+0.16% | 13.45B | |
+22.37% | 11.32B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating